SCHEMBL10131941

SCHEMBL10131941

Cc1nnc(CO)c(-c2ncccc2Cl)c1-c1ccc(Cl)cc1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
TRPV1 Q8NER1 2/20 0.36
MEN1 O00255 1/20 0.35
NPSR1 Q6W5P4 2/20 0.35
NOTUM Q6P988 1/20 0.35
TDP2 O95551 1/20 0.33
RORB Q92753 1/20 0.33
ALDH1A1 P00352 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KRAS P01116 1/20 0.33
PDE2A O00408 2/20 0.32
CRHR1 P34998 1/20 0.32
KDM4E B2RXH2 1/20 0.32
CACNA1B Q00975 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL896634 0.87 NPC1 (0.40) KMT2ANPC1RAB9ATRPV1MEN1
SCHEMBL896380 0.83 NPC1 (0.37) KMT2ANPC1RAB9ATRPV1MEN1
SCHEMBL896637 0.81 KMT2A (0.45) KMT2ANPC1RAB9ATRPV1MEN1
SCHEMBL1135703 0.76 TRPV1 (0.40) KMT2ANPC1RAB9ATRPV1MEN1
SCHEMBL896651 0.72 TRPV1 (0.45) KMT2ANPC1RAB9ATRPV1MEN1
SCHEMBL12457752 0.72 MEN1 (0.37) KMT2ANPC1RAB9AMEN1NOTUM
SCHEMBL12457753 0.71 MEN1 (0.36) KMT2ARAB9AMEN1NOTUMPDE2A
SCHEMBL896628 0.71 DRD1 (0.43) TRPV1NOTUM
SCHEMBL896518 0.70 KMT2A (0.38) KMT2ANPC1RAB9ATRPV1NPSR1
SCHEMBL10131946 0.69 KDM4E (0.36) KMT2ATRPV1NOTUMKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120083605-A1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083605-A1 PYRIDAZINE COMPOUND AND USE THEREOF PLPBP, PNPO, PDXK KMT2A 1894/4885NPC1 1560/4885RAB9A 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.